Although the MOMP‐effector function of tBID is less efficient than that of BAX and BAK, and thus it will likely not dominate under conditions when all effectors are activated, this newly recognized activity of tBID can be decisive in some (patho)‐physiological scenarios, like in the context of Shigella infection, or in tumours that have become resistant to BAX and BAK, as we report here. Here, BAK1 is linked to neoplasm.